Literature DB >> 2436200

Peptide-hormone- and serotonin-immunoreactive cells in normal and hyperplastic prostate glands.

P A Abrahamsson, L B Wadström, J Alumets, S Falkmer, L Grimelius.   

Abstract

Peptide-hormone- and serotonin-immunoreactive cells of endocrine type are present both in the normal prostatic gland and in the nodules of benign prostatic hyperplasia of man. They are located in the epithelium of the acini and the ducts of all the different parts of the gland, as well as in the urothelium of the prostatic part of the mucosa of the urethra. The endocrine cells are usually argyrophil, sometimes even argentaffin, and immunoreactive with neuron-specific enolase; they can be either of open or of closed type and usually occur widely scattered as single cells. Three kinds of endocrine cells were observed both in the normal gland and in the hyperplastic parenchyma. In the by far most prevalent type serotonin was found to co-exist with a peptide immunohistochemically related to the thyroid stimulating hormone (TSH). In a more rare type serotonin co-existed immunohistochemically with calcitonin. The third kind of endocrine cells was somatostatin-immunoreactive cells; they were also rather rare. The only difference observed between the normal and hyperplastic parenchyma was an increase in the number of all the three kinds of endocrine cells in the hyperplastic nodules. The endocrine cells could easily be visualized by means of silver-staining techniques, even using conventionally formalin-fixed, paraffin-embedded specimens.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2436200     DOI: 10.1016/s0344-0338(86)80043-7

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  13 in total

1.  Intraluminal volume homeostasis: A common sertonergic mechanism among diverse epithelia.

Authors:  Vaibhav P Pai; Aaron M Marshall
Journal:  Commun Integr Biol       Date:  2011-09-01

Review 2.  Morphologic and regulatory aspects of prostatic function.

Authors:  G Aumüller
Journal:  Anat Embryol (Berl)       Date:  1989

3.  Prostatic neuroendocrine tumor in multiple endocrine neoplasia Type 2B.

Authors:  B Goulet-Salmon; E Berthe; S Franc; S Chanel; F Galateau-Salle; M Kottler; J Mahoudeau; Y Reznik
Journal:  J Endocrinol Invest       Date:  2004-06       Impact factor: 4.256

4.  New approaches to the treatment of advanced prostate cancer.

Authors:  E T Goluboff; D Hirano; J B Thrasher; G Stark; G J Miller; L M Glodé
Journal:  Rev Urol       Date:  2001

5.  Prostate cancer and neuroendocrine differentiation.

Authors:  M O Tan; U Karaoğlan; B Celik; O Ataoğlu; H Biri; I Bozkirli
Journal:  Int Urol Nephrol       Date:  1999       Impact factor: 2.370

Review 6.  Neuroendocrine peptides in the prostate.

Authors:  P J Gkonos; A Krongrad; B A Roos
Journal:  Urol Res       Date:  1995

7.  Androgen receptor status in endocrine-paracrine cell types of the normal, hyperplastic, and neoplastic human prostate.

Authors:  H Bonkhoff; U Stein; K Remberger
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  Neuroendocrine differentiation in human prostatic tumor models.

Authors:  M A Noordzij; W M van Weerden; C M de Ridder; T H van der Kwast; F H Schröder; G J van Steenbrugge
Journal:  Am J Pathol       Date:  1996-09       Impact factor: 4.307

9.  Serotonin-, somatostatin- and chromogranin A-containing cells of the urethro-prostatic complex in the sheep. An immunocytochemical and immunofluorescent study.

Authors:  A Vittoria; E La Mura; T Cocca; A Cecio
Journal:  J Anat       Date:  1990-08       Impact factor: 2.610

10.  RNA interference of achaete-scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites.

Authors:  Yan Hu; Ting Wang; Gary D Stormo; Jeffrey I Gordon
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-01       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.